Company Spotlight: Cellect Biotechnology – RTTNews – RTT News

Shares of Cellect Biotechnology Ltd. (APOP) are up more than 44% over the last 5 trading days.

With its shares currently traded on both the NASDAQ and Tel Aviv Stock Exchange, Cellect is the company behind ApoGraft, a breakthrough technology for the isolation of stem cells from any given tissue.

Cellect's ApoGraft technology is aiming to turn stem cell transplants into a simple, safe and cost effective process, reducing the associated severe side effects, such as rejection and many other risks, such as Graft versus Host Disease.

Graft versus Host Disease, a condition in which the transplanted immune cells attack the recipient's cells, is a common complication associated with *allogeneic stem cell transplantation. (*Allogeneic stem cell transplantation involves transferring the stem cells to the recipient from a genetically matched relative or other donor).

The positive results from a clinical trial of ApoGraft that involved 104 healthy donors of blood stem cells reported in February of this year demonstrated that Cellect's ApoGraft is a safe, robust and reproducible process for clinical use.

According to the company, the use of the ApoGraft to process human stem cells for bone marrow transplantation resulted in a significant increase in the death of mature immune cells, primarily T Lymphocytes, without compromising the quantity and quality of stem cells. The process takes only a few hours as compared to days of complex and expansive lab work with traditional methods, is anticipated to be extremely cost effective in comparison to current approaches, and has the potential to significantly reduce the risk of GvHD.

The first blood cancer patient was treated in a phase I/II trial of ApoGraft in February of this year, and on March 27th, the company announced that the first stem cell transplant procedure has been successfully performed.

With the first stem cell transplant procedure being successful, Cellect has received the go-ahead from the independent Data and Safety Monitoring Board for enrolling additional 2 cancer patients for ApoGraft transplantation treatments.

The study is designed to enroll 12 patients.

Key Financials:

- Net loss for the fourth quarter ended December 31, 2016 was $0.75 million or $0.007 per share compared to a net loss of $0.96 million or $0.012 per share in Q4, 2015.

- Cash totaled $8.0 million at December 31, 2016 compared to $3.1 million on December 31, 2015.

- The number of shares outstanding is 107.58 million (Data sourced from Yahoo Finance).

In order to maximize the value of the Company for all stakeholders, Cellect plans to delist from the Tel Aviv Stock Exchange (TASE) in accordance with section 350 to the Israeli Company Law.

Shares of Cellect Biotechnology touched an all-time intra-day high of $13.50 on Mar.27, 2017 on the NASDAQ. The stock closed yesterday's trading at $8.98, up 2.75%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Read more:
Company Spotlight: Cellect Biotechnology - RTTNews - RTT News